Takeda Pharmaceutical (TAK) Tax Provisions (2017 - 2026)

Takeda Pharmaceutical has reported Tax Provisions for 10 years, with the latest figure at -$310.3 million in Q2 2026.

• On a quarterly basis, Tax Provisions fell 70.4% year-over-year to -$310.3 million in Q2 2026; TTM through Jun 2026 was -$717.5 million, a 12.68% decrease from a year earlier, with the FY2026 full-year figure at -$62.3 million, up 85.82% from the prior year.
• Tax Provisions was -$310.3 million for Q2 2026 at Takeda Pharmaceutical, up from -$315.6 million in the prior quarter.
• The five-year high for Tax Provisions was $562.7 million in Q4 2025, with the low at -$734.0 million in Q1 2022.
• Average Tax Provisions over 5 years is -$170.9 million, with a median of -$289.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Tax Provisions soared 1692.2% in 2023, then slumped 246.78% in 2024.
• Over 5 years, Tax Provisions stood at $84.9 million in 2022, then soared by 254.55% to $301.1 million in 2023, then decreased by 2.77% to $292.7 million in 2024, then surged by 92.24% to $562.7 million in 2025, then slumped by 155.15% to -$310.3 million in 2026.
• The last three Tax Provisions figures came in at -$310.3 million (Q2 2026), -$315.6 million (Q1 2026), and $562.7 million (Q4 2025), per Business Quant data.